Certolizumab pegol: a new biologic targeting rheumatoid arthritis

References

• Lee DM, Weinblatt ME. Rheumatoid arthritis. Lancet358(9285), 903–911 (2001).
   PubMed Web of Science ®Google Scholar
• Spector TD. Rheumatoid arthritis. Rheum. Dis. Clin. North Am.16(3), 513–537 (1990).
   PubMed Web of Science ®Google Scholar
• Silman AJ, Pearson JE. Epidemiology and genetics of rheumatoid arthritis. Arthritis Res.4(Suppl. 3), S265–S272 (2002).
   PubMedGoogle Scholar
• Fuchs HA, Kaye JJ, Callahan LF et al. Evidence of significant radiographic damage in rheumatoid arthritis within the first 2 years of disease. J. Rheumatol.16(5), 585–591 (1989).
   PubMed Web of Science ®Google Scholar
• Saag KG, Teng GG, Patkar NM et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum.59(6), 762–784 (2008).
   PubMed Web of Science ®Google Scholar
• Emery P, Van Vollenhoven R, Ostergaard M et al. Guidelines for initiation of anti-tumour necrosis factor therapy in rheumatoid arthritis: similarities and differences across Europe. Ann. Rheum. Dis.68(4), 456–459 (2009).
   PubMed Web of Science ®Google Scholar
• Svensson B, Boonen A, Albertsson K et al. Low-dose prednisolone in addition to the initial disease-modifying antirheumatic drug in patients with early active rheumatoid arthritis reduces joint destruction and increases the remission rate: a two-year randomized trial. Arthritis Rheum.52(11), 3360–3370 (2005).
   PubMed Web of Science ®Google Scholar
• Kirwan JR. The effect of glucocorticoids on joint destruction in rheumatoid arthritis. The Arthritis and Rheumatism Council Low-Dose Glucocorticoid Study Group. N. Engl. J. Med.333(3), 142–146 (1995).
   PubMed Web of Science ®Google Scholar
• O’Dell JR, Haire CE, Erikson N et al. Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications. N. Engl. J. Med.334(20), 1287–1291 (1996).
   PubMed Web of Science ®Google Scholar
• St Clair EW, van der Heijde DM, Smolen JS et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum.50(11), 3432–3443 (2004).
   PubMed Web of Science ®Google Scholar
• Breedveld FC, Weisman MH, Kavanaugh AF et al. The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum.54(1), 26–37 (2006).
   PubMed Web of Science ®Google Scholar
• Emery P, Breedveld FC, Hall S et al. Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial. Lancet372(9636), 375–382 (2008).
   PubMed Web of Science ®Google Scholar
• Boers M. Cost–effectiveness of biologics as first-line treatment of rheumatoid arthritis: case closed? Ann. Intern. Med.151(9), 668–669 (2009).
   PubMed Web of Science ®Google Scholar
• Maini R, St Clair EW, Breedveld F et al. Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised Phase III trial. ATTRACT Study Group. Lancet354(9194), 1932–1939 (1999).
   PubMed Web of Science ®Google Scholar
• van Vollenhoven RF, Ernestam S, Harju A et al. Etanercept versus etanercept plus methotrexate: a registry-based study suggesting that the combination is clinically more efficacious. Arthritis Res.Ther.5(6), R347–R351 (2003).
   PubMed Web of Science ®Google Scholar
• Weinblatt ME, Keystone EC, Furst DE et al. Adalimumab, a fully human anti-tumor necrosis factor α monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum.48(1), 35–45 (2003).
   PubMed Web of Science ®Google Scholar
• Genovese MC, Bathon JM, Martin RW et al. Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes. Arthritis Rheum.46(6), 1443–1450 (2002).
   PubMed Web of Science ®Google Scholar
• Lipsky PE, van der Heijde DM, St Clair EW et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N. Engl. J. Med.343(22), 1594–1602 (2000).
   PubMed Web of Science ®Google Scholar
• Keystone EC, Kavanaugh AF, Sharp JT et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum.50(5), 1400–1411 (2004).
   PubMed Web of Science ®Google Scholar
• Cohen SB, Emery P, Greenwald MW et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, Phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum.54(9), 2793–2806 (2006).
   PubMed Web of Science ®Google Scholar
• Genovese MC, Becker JC, Schiff M et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor α inhibition. N. Engl. J. Med.353(11), 1114–1123 (2005).
   PubMed Web of Science ®Google Scholar
• Emery P, Keystone E, Tony HP et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann. Rheum. Dis.67(11), 1516–1523 (2008).
   PubMed Web of Science ®Google Scholar
• van Vollenhoven R, Harju A, Brannemark S et al. Treatment with infliximab (Remicade) when etanercept (Enbrel) has failed or vice versa: data from the STURE registry showing that switching tumour necrosis factor α blockers can make sense. Ann. Rheum. Dis.62(12), 1195–1198 (2003).
   PubMed Web of Science ®Google Scholar
• Smolen JS, Kay J, Doyle MK et al. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor α inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, Phase III trial. Lancet374(9685), 210–221 (2009).
   PubMed Web of Science ®Google Scholar
• Emery P, Kosinski M, Li T et al. Treatment of rheumatoid arthritis patients with abatacept and methotrexate significantly improved health-related quality of life. J. Rheumatol.33(4), 681–689 (2006).
   PubMed Web of Science ®Google Scholar
• Kremer JM, Genant HK, Moreland LW et al. Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial. Ann. Intern. Med.144(12), 865–876 (2006).
   PubMed Web of Science ®Google Scholar
• Smolen JS, Beaulieu A, Rubbert-Roth A et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet371(9617), 987–997 (2008).
   PubMed Web of Science ®Google Scholar
• Fleischmann RM, Schechtman J, Bennett R et al. Anakinra, a recombinant human interleukin-1 receptor antagonist (r-metHuIL-1ra), in patients with rheumatoid arthritis: a large, international, multicenter, placebo-controlled trial. Arthritis Rheum.48(4), 927–934 (2003).
   PubMed Web of Science ®Google Scholar
• Cohen SB, Dore RK, Lane NE et al. Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, Phase II clinical trial. Arthritis Rheum.58(5), 1299–1309 (2008).
   PubMed Web of Science ®Google Scholar
• Genovese MC, Kaine JL, Lowenstein MB et al. Ocrelizumab, a humanized anti-CD20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a Phase I/II randomized, blinded, placebo-controlled, dose-ranging study. Arthritis Rheum.58(9), 2652–2661 (2008).
   PubMed Web of Science ®Google Scholar
• Senolt L, Vencovsky J, Pavelka K et al. Prospective new biological therapies for rheumatoid arthritis. Autoimmun. Rev.9(2), 102–107 (2009).
   PubMed Web of Science ®Google Scholar
• Church LD, McDermott MF. Canakinumab, a fully-human mAb against IL-1β for the potential treatment of inflammatory disorders. Curr. Opin. Mol. Ther.11(1), 81–89 (2009).
   PubMed Web of Science ®Google Scholar
• Baslund B, Tvede N, Danneskiold-Samsoe B et al. Targeting interleukin-15 in patients with rheumatoid arthritis: a proof-of-concept study. Arthritis Rheum.52(9), 2686–2692 (2005).
   PubMed Web of Science ®Google Scholar
• Plater-Zyberk C, Joosten LA, Helsen MM et al. Combined blockade of granulocyte-macrophage colony stimulating factor and interleukin 17 pathways potently suppresses chronic destructive arthritis in a tumour necrosis factor α-independent mouse model. Ann. Rheum. Dis.68(5), 721–728 (2009).
   PubMed Web of Science ®Google Scholar
• Leonardi CL, Kimball AB, Papp KA et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet371(9625), 1665–1674 (2008).
   PubMed Web of Science ®Google Scholar
• Yago T, Nanke Y, Kawamoto M et al. IL-23 induces human osteoclastogenesis via IL-17 in vitro, and anti-IL-23 antibody attenuates collagen-induced arthritis in rats. Arthritis Res. Ther.9(5), R96 (2007).
   PubMed Web of Science ®Google Scholar
• Tak PP, Thurlings RM, Rossier C et al. Atacicept in patients with rheumatoid arthritis: results of a multicenter, Phase Ib, double-blind, placebo-controlled, dose-escalating, single- and repeated-dose study. Arthritis Rheum.58(1), 61–72 (2008).
   PubMed Web of Science ®Google Scholar
• Robak T. Ofatumumab, a human monoclonal antibody for lymphoid malignancies and autoimmune disorders. Curr. Opin. Mol. Ther.10(3), 294–309 (2008).
   PubMed Web of Science ®Google Scholar
• Kremer JM, Bloom BJ, Breedveld FC et al. The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: results of a double-blind, placebo-controlled Phase IIa trial of three dosage levels of CP-690,550 versus placebo. Arthritis Rheum.60(7), 1895–1905 (2009).
   PubMed Web of Science ®Google Scholar
• Weinblatt ME, Kavanaugh A, Burgos-Vargas R et al. Treatment of rheumatoid arthritis with a Syk kinase inhibitor: a twelve-week, randomized, placebo-controlled trial. Arthritis Rheum.58(11), 3309–3318 (2008).
   PubMed Web of Science ®Google Scholar
• Nesbitt A, Fossati G, Bergin M et al. Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti-tumor necrosis factor α agents. Inflamm. Bowel Dis.13(11), 1323–1332 (2007).
   PubMed Web of Science ®Google Scholar
• Keystone E, Heijde D, Mason D Jr et al. Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, Phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum.58(11), 3319–3329 (2008).
   PubMed Web of Science ®Google Scholar
• Fleischmann R, Vencovsky J, van Vollenhoven RF et al. Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study. Ann. Rheum. Dis.68(6), 805–811 (2009).
   PubMed Web of Science ®Google Scholar
• Smolen J, Landewe RB, Mease P et al. Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial. Ann. Rheum. Dis.68(6), 797–804 (2009).
   PubMed Web of Science ®Google Scholar
• Keystone E, Fleischmann R, Smolen J et al. The efficacy of certolizumab pegol added to methotrexate is sustained over 2 years in the treatment of rheumatoid arthritis. Arthritis Rheum.60(Suppl. 9) (2009) (Abstract 1666).
   PubMedGoogle Scholar
• Strand V, Fleischmann R, Kvien TK et al. Certolizumab pegol added to methotrexate provides lasting improvements in patient-reported outcomes over 2 years. Arthritis Rheum.60(Suppl. 9) (2009) (Abstract 1698).
   Google Scholar
• Strand V, Mease P, Burmester GR et al. Rapid and sustained improvements in health-related quality of life, fatigue, and other patient-reported outcomes in rheumatoid arthritis patients treated with certolizumab pegol plus methotrexate over 1 year: results from the RAPID 1 randomized controlled trial. Arthritis Res. Ther.11(6), R170 (2009).
   PubMed Web of Science ®Google Scholar
• Kavanaugh A, Smolen JS, Emery P et al. Effect of certolizumab pegol with methotrexate on home and work place productivity and social activities in patients with active rheumatoid arthritis. Arthritis Care Res.61(11), 1592–1600 (2009).
   Web of Science ®Google Scholar
• Arnett FC, Edworthy SM, Bloch DA et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum.31(3), 315–324 (1988).
   PubMed Web of Science ®Google Scholar
• Felson DT, Anderson JJ, Boers M et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum.38(6), 727–735 (1995).
   PubMed Web of Science ®Google Scholar
• van der Heijde DM, van Riel PL, Nuver-Zwart IH et al. Effects of hydroxychloroquine and sulphasalazine on progression of joint damage in rheumatoid arthritis. Lancet1(8646), 1036–1038 (1989).
   PubMed Web of Science ®Google Scholar
• Bruce B, Fries JF. The Stanford Health Assessment Questionnaire: a review of its history, issues, progress, and documentation. J. Rheumatol.30(1), 167–178 (2003).
   PubMed Web of Science ®Google Scholar
• Strand V, Scott DL, Emery P et al. Physical function and health related quality of life: analysis of 2-year data from randomized, controlled studies of leflunomide, sulfasalazine, or methotrexate in patients with active rheumatoid arthritis. J. Rheumatol.32(4), 590–601 (2005).
   PubMed Web of Science ®Google Scholar
• McHorney CA, Ware JE Jr, Raczek AE. The MOS 36-Item Short-Form Health Survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs. Med. Care31(3), 247–263 (1993).
   PubMed Web of Science ®Google Scholar
• Tack BB. Self-reported fatigue in rheumatoid arthritis. A pilot study. Arthritis Care Res.3(3), 154–157 (1990).
   PubMedGoogle Scholar
• Farrar JT, Young JP Jr, LaMoreaux L et al. Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain94(2), 149–158 (2001).
   PubMed Web of Science ®Google Scholar
• Osterhaus JT, Purcaru O, Richard L. Discriminant validity, responsiveness and reliability of the rheumatoid arthritis-specific Work Productivity Survey (WPS-RA). Arthritis Res. Ther.11(3), R73 (2009).
   PubMed Web of Science ®Google Scholar
• Bendele A, Seely J, Richey C et al. Short communication: renal tubular vacuolation in animals treated with polyethylene-glycol-conjugated proteins. Toxicol. Sci.42(2), 152–157 (1998).
   PubMed Web of Science ®Google Scholar
• Webster R, Didier E, Harris P et al. PEGylated proteins: evaluation of their safety in the absence of definitive metabolism studies. Drug Metab. Dispos.35(1), 9–16 (2007).
   PubMed Web of Science ®Google Scholar
• Klareskog L, van der Heijde D, de Jager JP et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet363(9410), 675–681 (2004).
   PubMed Web of Science ®Google Scholar
• Moreland LW, Schiff MH, Baumgartner SW et al. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann. Intern. Med.130(6), 478–486 (1999).
   PubMed Web of Science ®Google Scholar
• van de Putte LB, Atkins C, Malaise M et al. Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann. Rheum. Dis.63(5), 508–516 (2004).
   PubMed Web of Science ®Google Scholar
• Bathon JM, Martin RW, Fleischmann RM et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N. Engl. J. Med.343(22), 1586–1593 (2000).
   PubMed Web of Science ®Google Scholar